157 related articles for article (PubMed ID: 19689285)
1. HSP90 inhibitors: multi-targeted antitumor effects and novel combinatorial therapeutic approaches in cancer therapy.
Hwang M; Moretti L; Lu B
Curr Med Chem; 2009; 16(24):3081-92. PubMed ID: 19689285
[TBL] [Abstract][Full Text] [Related]
2. Macrocyclic inhibitors of hsp90.
Johnson VA; Singh EK; Nazarova LA; Alexander LD; McAlpine SR
Curr Top Med Chem; 2010; 10(14):1380-402. PubMed ID: 20536417
[TBL] [Abstract][Full Text] [Related]
3. Role of oxidative stress in geldanamycin-induced cytotoxicity and disruption of Hsp90 signaling complex.
Clark CB; Rane MJ; El Mehdi D; Miller CJ; Sachleben LR; Gozal E
Free Radic Biol Med; 2009 Nov; 47(10):1440-9. PubMed ID: 19703551
[TBL] [Abstract][Full Text] [Related]
4. Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions.
Jhaveri K; Ochiana SO; Dunphy MP; Gerecitano JF; Corben AD; Peter RI; Janjigian YY; Gomes-DaGama EM; Koren J; Modi S; Chiosis G
Expert Opin Investig Drugs; 2014 May; 23(5):611-28. PubMed ID: 24669860
[TBL] [Abstract][Full Text] [Related]
5. Targeting Hsp90 in urothelial carcinoma.
Chehab M; Caza T; Skotnicki K; Landas S; Bratslavsky G; Mollapour M; Bourboulia D
Oncotarget; 2015 Apr; 6(11):8454-73. PubMed ID: 25909217
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Efficacy of Lactonic Sophorolipids: Nanoceria-Assisted Combination Therapy of NSCLC using HDAC and Hsp90 Inhibitors.
Naz S; Banerjee T; Totsingan F; Woody K; Gross RA; Santra S
Nanotheranostics; 2021; 5(4):391-404. PubMed ID: 33912379
[No Abstract] [Full Text] [Related]
7. Update on Hsp90 inhibitors in clinical trial.
Kim YS; Alarcon SV; Lee S; Lee MJ; Giaccone G; Neckers L; Trepel JB
Curr Top Med Chem; 2009; 9(15):1479-92. PubMed ID: 19860730
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy involving HSP90 inhibitors for combating cancer: an overview of clinical and preclinical progress.
Liu Y; Li C; Liu H; Tan S
Arch Pharm Res; 2024 Apr; ():. PubMed ID: 38632167
[TBL] [Abstract][Full Text] [Related]
9. Prospects and challenges of noncoding-RNA-mediated inhibition of heat shock protein 90 for cancer therapy.
Mattoo S; Gupta A; Chauhan M; Agrawal A; Pore SK
Biochim Biophys Acta Gene Regul Mech; 2024 Mar; 1867(1):195006. PubMed ID: 38218528
[TBL] [Abstract][Full Text] [Related]
10. Inhibiting the molecular evolution of cancer through HSP90.
Martins AS; Davies FE; Workman P
Oncotarget; 2012 Oct; 3(10):1054-6. PubMed ID: 23175477
[No Abstract] [Full Text] [Related]
11. Advances in molecular targeted therapies to increase efficacy of (chemo)radiation therapy.
Viktorsson K; Rieckmann T; Fleischmann M; Diefenhardt M; Hehlgans S; Rödel F
Strahlenther Onkol; 2023 Dec; 199(12):1091-1109. PubMed ID: 37041372
[TBL] [Abstract][Full Text] [Related]
12. Anticancer drugs: How to select small molecule combinations?
Nussinov R; Yavuz BR; Jang H
Trends Pharmacol Sci; 2024 May; ():. PubMed ID: 38782689
[TBL] [Abstract][Full Text] [Related]
13. Circumventing HSP90 inhibitors via apoptosis block.
Fennell DA; Busacca S
Oncoscience; 2015; 2(9):747-8. PubMed ID: 26501078
[No Abstract] [Full Text] [Related]
14. Binding Mechanism of Inhibitors to Heat Shock Protein 90 Investigated by Multiple Independent Molecular Dynamics Simulations and Prediction of Binding Free Energy.
Yang F; Wang Y; Yan D; Liu Z; Wei B; Chen J; He W
Molecules; 2023 Jun; 28(12):. PubMed ID: 37375347
[TBL] [Abstract][Full Text] [Related]
15. Dynamics revelation of conformational changes and binding modes of heat shock protein 90 induced by inhibitor associations.
Chen J; Wang J; Lai F; Wang W; Pang L; Zhu W
RSC Adv; 2018 Jul; 8(45):25456-25467. PubMed ID: 35539786
[TBL] [Abstract][Full Text] [Related]
16. More than efficacy revealed by single-cell analysis of antiviral therapeutics.
Liu W; Caglar MU; Mao Z; Woodman A; Arnold JJ; Wilke CO; Cameron CE
Sci Adv; 2019 Oct; 5(10):eaax4761. PubMed ID: 31692968
[TBL] [Abstract][Full Text] [Related]
17. The heat shock protein 90 inhibitor SNX5422 has a synergistic activity with histone deacetylase inhibitors in induction of death of anaplastic thyroid carcinoma cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Endocrine; 2016 Feb; 51(2):274-82. PubMed ID: 26219406
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic heat shock protein 70 induction confers cytoprotection against inflammation in gliovascular cells.
Kacimi R; Yenari MA
Glia; 2015 Jul; 63(7):1200-12. PubMed ID: 25802219
[TBL] [Abstract][Full Text] [Related]
19. Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression.
He S; Zhang C; Shafi AA; Sequeira M; Acquaviva J; Friedland JC; Sang J; Smith DL; Weigel NL; Wada Y; Proia DA
Int J Oncol; 2013 Jan; 42(1):35-43. PubMed ID: 23152004
[TBL] [Abstract][Full Text] [Related]
20. 18β-glycyrrhetinic acid potentiates Hsp90 inhibition-induced apoptosis in human epithelial ovarian carcinoma cells via activation of death receptor and mitochondrial pathway.
Yang JC; Myung SC; Kim W; Lee CS
Mol Cell Biochem; 2012 Nov; 370(1-2):209-19. PubMed ID: 22865487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
